SELLAS Life Sciences (SLS) Cash from Discontinued Operations (2014 - 2017)
SELLAS Life Sciences (SLS) posted quarterly Cash from Discontinued Operations of 2449000.0 for Q3 2017, down 20.28% year-over-year from 3072189.77 in Q3 2016, and up 1.41% quarter-over-quarter from 2484000.0 in Q2 2017.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Cash from Discontinued Operations (2014 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Cash from Discontinued Operations for 4 consecutive years, with 2449000.0 the latest figure, recorded in Q3 2017.
- In Q3 2017, Cash from Discontinued Operations fell 20.28% year-over-year to 2449000.0; the TTM figure through Sep 2017 stood at 12467000.0 (up 7.42% YoY), while the FY2016 annual figure was 11685000.0, down 24.87% from the prior year.
- Cash from Discontinued Operations climbed to 2449000.0 in Q3 2017 per SLS's latest filing, from 2484000.0 in the prior quarter.
- Across five years, Cash from Discontinued Operations topped out at 1059000.0 in Q1 2015 and bottomed at 5004000.0 in Q1 2017.
- Historically, Cash from Discontinued Operations has averaged 2785000.0 across 4 years, with a median of 2507000.0 in 2016.
- On a YoY basis, Cash from Discontinued Operations climbed as much as 41.31% in 2016 and fell as far as 228.14% in 2016.
- SELLAS Life Sciences' Cash from Discontinued Operations stood at 2440000.0 in 2014, then sank by 76.68% to 4311000.0 in 2015, then jumped by 41.31% to 2530000.0 in 2016, then climbed by 3.2% to 2449000.0 in 2017.
- Business Quant data shows SLS's Cash from Discontinued Operations at 2449000.0 in Q3 2017, 2484000.0 in Q2 2017, and 5004000.0 in Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.65 Bn | 2.65 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | -2.45 Mn |
| Jun 30, 2017 | -2.48 Mn |
| Mar 31, 2017 | -5.00 Mn |
| Dec 31, 2016 | -2.53 Mn |
| Sep 30, 2016 | -2.04 Mn |
| Jun 30, 2016 | -3.64 Mn |
| Mar 31, 2016 | -3.48 Mn |
| Dec 31, 2015 | -4.31 Mn |
| Sep 30, 2015 | -1.07 Mn |
| Jun 30, 2015 | -2.92 Mn |
| Mar 31, 2015 | -1.06 Mn |
| Dec 31, 2014 | -2.44 Mn |